drugset / Trial / NCT03567629
Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
Phase 2
Unknown
130 enrolled
Peking University
Liaoning Cancer Hospital & Institute · collabZhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, open-lable, multicenter, randomized, controlled, phase II clinical study. The aim is to evaluate the efficacy of Irinotecan versus Oxaliplatin in the first-line treatment of refractory metastatic colorectal cancer.
Timeline
- Start
- 2018-05-29
- Primary completion
- 2021-12-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Comparator | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Comparator | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | S-1 | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |